Key Findings
City of Hope investigators have demonstrated a preclinical platform for chimeric antigen receptor (CAR) T cells that allows for the addition of engineered molecules after the cells have been infused. In animal studies published in Cancer Immunology Research on September 7, 2026, these “meCAR T” cells were shown to accept different add-ons to support cell tracking, promote growth, and expand the range of recognized cancer cells.
Technical Details
The platform utilizes “meditope,” a molecular docking technology. Unlike conventional CAR T cells where functions are hardwired into the receptor, the meCAR T architecture separates the recognition machinery from adaptor molecules. This modular design allows the cells to connect with a small molecule called meP. By pairing the cells with different adaptor configurations, researchers can provide or modify specific capabilities without rebuilding the cell’s receptor. This process is compared to updating smartphone software, where new instructions are sent to cells already present in the body.
Background & Context
Current CAR T therapies are largely fixed after infusion, making them inflexible when tumors evolve or develop escape mechanisms. This lack of adaptability often leads to treatment failure and relapse, particularly in solid tumors where malignant cells exhibit molecular heterogeneity. John Williams, Ph.D., and Christine Brown, Ph.D., developed this platform to ensure therapeutic cells can adapt as tumors progress.
Significance & Outlook
The modular design potentially allows clinicians to adjust treatment as the target landscape changes, which may be particularly effective against the barriers found in solid tumors. While the current results are limited to preclinical animal experiments, the researchers are developing two Phase I clinical trials. These trials will evaluate the safety and activity of meCAR T cells in patients with acute myeloid leukemia and solid tumors. City of Hope holds equity and royalty interests in Meditope Biosciences Inc., which has licensed the core technology.
Source: https://bioengineer.org/preclinical-plug-and-play-car-t-cells-can-be-reconfigured-after-treatment/
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
